The ever-increasing cases and mortality due to malaria remains one of the most important public health threats, especially in sub-Saharan Africa—where this burden is considerably high. In 2020, sub-Saharan Africa accounted for about 95% of all cases and 96% of all malaria deaths with about 80% of these deaths reported in children under the age of 5. This review, adopting a public health focus, aimed to understand the challenges of malaria control in sub-Saharan Africa despite ongoing public health interventions. Our review highlights two important findings. First, the increasing resistance of malaria parasites to artemisinin-based combination therapy (ACT) and its partner drugs coupled with increased vector resistance to pyrethroids and insecticides is reversing the progress of public health interventions in keeping malaria under control. Second, the wanning for the efficacy of the WHO-approved vaccine i.e. RTS,S from 60 to 70% following 18 months of observation, and its short-term availability remains an impediment to achieving the WHO target of producing malaria vaccines with more than 75% efficacy by 2030. Our findings underline the need to reassess research priorities with a focus on vaccine production in sub-Saharan Africa. Furthermore, African governments and policymakers must be committed to invest both the political and financial capital in vaccine production and distribution.

Rapid deforestation and unprecedented wildlife trafficking are important factors triggering the rate of zoonotic spillover from animals to humans. Consequently, this leads to the emergence and re-emergence of zoonotic infectious diseases among the human population. Deforestation is an important ecological disruption that leads to the loss of biodiversity. The loss of biodiversity results in the persistence of highest-quality hosts of zoonotic pathogens dominating the low-diversity communities, a process termed the dilution effect. Activities like intensive farming and logging that resulted in deforestation bring vulnerable people in close contact with these highest-quality reservoir hosts (wildlife). As a result of this vulnerability, there is an increased risk of spillover, leading to zoonotic infection in humans and eventually disease outbreaks during human–human transmission. One prominent example of a disease of wildlife origin is the ongoing SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2), even though the original source has not been found. Another important factor facilitating the risk of spillover and emergence of zoonotic infectious diseases is wildlife trafficking. This involves illegal hunting and trading of wildlife and their products, which increases the risk of spillover as a result of exchange of bodily fluids and bloodmeals between humans and wildlife during the hunting and butchering of animals’ carcasses. Consequently, little or no hygiene protocol and poor handling practices during the wildlife-trade chain expose poachers, consumers, and local market sellers to the risk of zoonotic diseases. Despite the interventions on deforestation-induced spillover and wildlife trafficking-associated spillover, there are still knowledge and research gaps that need to be addressed towards preventing the outbreaks of future zoonotic infectious diseases. In response to this, there is a need for interdisciplinary and intersectoral collaborations among researchers from various fields as well as sectors in minimizing the risk of zoonotic spillover driven by deforestation and wildlife trafficking at the human–animal–environmental nexus. In addition, there is a need for integrated and unified evidence-based policy formulation that puts an end to deforestation and wildlife trafficking, especially in tropical areas such as Africa and Asia.

Background: The rising circulation of the monkeypox virus while the COVID-19 is still ongoing in non-endemic countries is a significant global health threat. In this article, we have discussed the epidemiology, aetiology, and pathogenesis of the monkeypox virus to provide our current knowledge of the disease. Also, we discussed the ongoing efforts of the international health organizations to curtail the present epidemic and we finally provide recommendations for early detection and response. Methods: We did a rapid literature search on PubMed, EMBASE, World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other trusted databases for recent articles (1958-2022) published in English—focusing on the outbreaks of monkeypox disease, epidemiology, pathogenesis, aetiology, prevention, and control in endemic and non-endemic countries. Keywords such as "Monkeypox", "Monkeypox virus", "Poxviridae", "Orthopoxvirus", "Smallpox", and "Smallpox Vaccine" were considered in our search based on MESH medical subject headings. Results: Our review highlights four important findings. First, a cumulative of 1285 monkeypox cases have been documented and reported by the WHO in non-endemic countries as of June 8, 2022. Second, international travel contributes to the increase in cases in non-endemic countries. Third, the origin of the outbreak, the pattern of transmission, and the risk of infections is not fully understood. Fourth, there is an ongoing effort by the WHO, CDC, and other international health organization to control the spread of the monkeypox disease. Conclusion: Our findings underline the need to reassess research priorities on the origin, transmission pattern, and risk factors for infection of monkeypox. Also, we provide recommendations under the One Health spectrum to prevent further spread of the disease.

Arboviruses are most prevalent in tropical and subtropical regions, where arthropods are widespread. The World Health Organization (WHO) estimated that the mortality burden of arbovirus diseases, such as yellow fever in Africa, was 84,000–170,000 severe cases and 29,000–60,000 deaths in 2013. These epidemics emphasize the urgent need for integrated control and prevention of arboviral diseases. Challenges in managing and controlling arboviral diseases in Africa are mainly attributed to poor insect vector control, insecticide resistance, and poor sanitation and solid waste management. The removal or reduction of mosquito populations amongst susceptible individuals is identified as the most effective measure to control many vector-borne diseases. Current public health needs call for efficient vector control programs and maintenance of adequate surveillance systems through the availability of trained personnel and rapid diagnostic facilities, providing an interdisciplinary response to control and mitigate the threats of emerging and re-emerging arboviruses. Furthermore, research priorities should focus on understanding the factors responsible for adaptation to other vectors, determinants of infection and transmission, and the development of high efficiency antiviral molecules or candidate vaccines. Here, we explore and review our current understanding of arboviruses of public health importance in Africa, with a focus on emerging arboviruses, their arthropod vectors, and the epidemiology of major arboviruses. Finally, we appraise the role of planetary health in addressing the threat of arboviruses and identify other priority areas of research for effective control.

Introduction: Parkinson's disease (PD) is a neurodegenerative disorder that affects more than 10 million individuals worldwide. It is characterized by motor and sensory deficits. Research studies have increasingly demonstrated a correlation between Parkinson's disease and alternations in the composition of the gut microbiota in affected patients. Also, the significant role of prebiotics and probiotics in gastrointestinal and neurological conditions is imperative to understand their relation to Parkinson's disease.Method: To explore the scientific interaction of the gut‐microbiota‐brain axis and its association with Parkinson's disease, a comprehensive narrative review of the relevant literature was conducted. Articles were retrieved systematically from reputable sources, including PubMed, Science Direct, World Health Organization (WHO), and Advanced Google Scholar. Key search terms included are “Parkinson's Disease”, “Gut Microbiome”, “Braak's Theory”, “Neurological Disorders”, and “Gut‐brain axis”. Articles included in our review are published in English and they provide detailed information on the relationship between Parkinson's disease and gut microbiotaResults: This review highlights the impact of gut microbiota composition and associated factors on the progression of Parkinson's disease. Evidence‐based studies highlighting the existing evidence of the relationship between Parkinson's disease and alteration in gut microbiota are discussed. Consequently, the potential mechanisms by which the gut microbiota may affect the composition of the gut microbiota were revealed, with a particular emphasis on the role of the gut‐brain axis in this interplay.Conclusion: Understanding the complex interplay between gut microbiota and Parkinson's disease is a potential implication for the development of novel therapeutics against Parkinson's disease. Following the existing relationship demonstrated by different evidence‐based studies on Parkinson's disease and gut microbiota, our review concludes by providing recommendations and suggestions for future research studies with a particular emphasis on the impact of the microbiota‐brain axis on Parkinson's disease.

Background: In the era of insecticides and anti-malarial drug resistance, gene drive technology holds considerable promise for malaria control. Gene drive technology deploys genetic modifications into mosquito populations to impede their ability to transmit the malaria parasite. This can be either through the disruption of an essential mosquito gene or the association of gene drive with a desirable effector gene. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing tool that precisely modifies mosquito vector DNA sequences and curtails the rate of pathogen transmission.Methods: A comprehensive search was conducted in the SCOPUS and MEDLINE databases (via PubMed) until October 2023. The keywords used were related to the principles and mechanisms of gene drive technology, its advantages, and disadvantages, and its ethical and regulatory considerations in sustainable malaria eradication.Results: The development of gene drive enables the preferential inheritance of specific genes in targeted mosquitoes, potentially obstructing the transmission of the Plasmodium parasite. This technology was also studied for the control of other vector-borne diseases such as dengue and chikungunya viruses. Despite its experimental superiority over other traditional methods such as insecticide-treated nets and insecticide sprays, the long-term dynamic interplay of mutation and resistance poses challenges for gene drive efficiency in sustainable malaria control.Conclusions: This commentary elucidates the underlying mechanisms and principles of gene drive technology, underscoring its promise and challenges as a novel strategy to curtail malaria prevalence. Although the release of such genetically modified mosquitoes into the natural environment would result in the eradication of the locally targeted species of mosquitoes, the complete eradication of the entire species remains questionable. Thus, the practical application raises significant ethical and regulatory concerns for further research and risk assessment, including the risk of gene drive spreading to nontarget species in the wider theatre of biodiverse species.